UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2020

PROPHASE LABS, INC. (Exact name of Company as specified in its charter)				
Delaware (State or other jurisdiction of incorporation)	000-21617 (Commission File Number)	23-2577138 (I.R.S. Employer Identification No.)		
621 N. Shady Retreat Road Doylestown, PA (Address of principal executive of		18901 (Zip Code)		
Company's telephone number, including area co	ode: (215) 345-0919			
Check the appropriate box below if the Form under any of the following provisions (see General Control of the following provisions)		ously satisfy the filing obligation of the Company		
[] Written communications pursuant to R	cule 425 under the Securities Act (17	CFR 230.425)		
[] Soliciting material pursuant to Rule 14	la-12 under the Exchange Act (17 CF	FR 240.14a-12)		
[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
[] Pre-commencement communications p	oursuant to Rule 13e-4(c) under the F	Exchange Act (17 CFR 240.13e-4(c))		
Securities Registered Pursuant to Section 12(b)	of the Exchange Act:			
Title of Each Class Common Stock, par value \$0.0005	Trading Symbol PRPH	Name of Each Exchange on Which Registered Nasdaq Capital Market		
ndicate by check mark whether the registrant §230.405 of this chapter) or Rule 12b-2 of the		defined in Rule 405 of the Securities Act of 1933 40.12b-2 of this chapter).		
		Emerging growth company []		
f an emerging growth company, indicate by complying with any new or revised financial ac	e e e e e e e e e e e e e e e e e e e	ected not to use the extended transition period for at to Section 13(a) of the Exchange Act. []		

Item 7.01 Regulation FD Disclosure

On November 10, 2020, ProPhase Labs, Inc. issued a press release announcing that it will present at the Virtual Fall Investor Summit taking place November 16-18, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.

Item 9.01 Financial Statements and Exhibits.

/	11	-			
1	d١	Ex	hı	hi	tc
٠,	u,	டம	ш	υı	w

No.	Description
99.1	Press Release dated November 10, 2020

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ProPhase Labs, Inc.

By: /s/ Monica Brady

Monica Brady Chief Financial Officer

Date: November 10, 2020



ProPhase Labs to Present at the Virtual Fall Investor Summit on Monday, November 16, 2020 at 2:30 p.m. Eastern Time

DOYLESTOWN, PA – **November 10, 2020** – ProPhase Labs, Inc. (NASDAQ: PRPH) ("ProPhase Labs"), a diversified medical science and technology company, today announced that management will present at the Virtual Fall Investor Summit taking place November 16th – 18th, 2020.

ProPhase Labs CEO Ted Karkus is scheduled to host a virtual presentation during the conference and will also participate in one-on-one meetings throughout the day. Management will highlight its recent formation of ProPhase Diagnostics, which just completed the acquisition of a Clinical Laboratory Improvement Amendments ("CLIA") accredited laboratory in Old Bridge, New Jersey, and introduce Steven Kamalic, who was recently appointed COO of ProPhase Diagnostics. Steven is an 18-year industry veteran who recently oversaw a prominent east coast CLIA accredited laboratory and achieved record annual revenue growth to \$160 million during his ten-year tenure.

Virtual Fall Investor Summit

Date: Monday, November 16, 2020 Time: 2:30 p.m. EST, 11:30 a.m. PST

Webcast: https://www.webcaster4.com/Webcast/Page/2038/38517

Location: Virtual

For more information or to schedule a one-on-one meeting with ProPhase Labs management, please contact your conference representative or you may also email your request to PRPH@mzgroup.us or call Chris Tyson at (949) 491-8235.

About ProPhase Labs

ProPhase Labs (NASDAQ: PRPH) is a diversified medical science and technology company with deep experience with OTC consumer healthcare products and dietary supplements. It's dietary supplement line of products, TK Supplements, has extensive distribution in major FDM (Food, Drug and Mass) retailers including Walmart, Walgreens, CVS and RITE-AID. The Company's recently formed wholly-owned subsidiary, ProPhase Diagnostics, Inc., is a rapidly developing CLIA laboratory business that offers COVID-19 and other Respiratory Pathogen Panel (RPP) testing services. ProPhase Labs is dedicated to creating sustainable value for shareholders over the long-term through growth of its existing businesses. It is also continuing to explore strategic investments and additional acquisition opportunities. For more information visit us at www.ProPhaselabs.com.

Investor Contact:

Chris Tyson Managing Director MZ Group - MZ North America 949-491-8235 PRPH@mzgroup.us www.mzgroup.us